Clinical Applications of Platelet-Rich Plasma in Patellar Tendinopathy
Author(s) -
Dayun Jeong,
Cholong Lee,
Jung Hun Lee,
Jaewoo Pak,
LinWoo Kang,
Byeong Chul Jeong,
Sang Hee Lee
Publication year - 2014
Publication title -
biomed research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 126
eISSN - 2314-6141
pISSN - 2314-6133
DOI - 10.1155/2014/249498
Subject(s) - platelet rich plasma , tendinopathy , medicine , growth factor , platelet derived growth factor receptor , vascular endothelial growth factor , transforming growth factor , fibroblast growth factor , platelet derived growth factor , epidermal growth factor , fibrosis , angiogenesis , cancer research , tendon , platelet , pathology , vegf receptors , receptor
Platelet-rich plasma (PRP), a blood derivative with high concentrations of platelets, has been found to have high levels of autologous growth factors (GFs), such as transforming growth factor- β (TGF- β ), platelet-derived growth factor (PDGF), fibroblastic growth factor (FGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). These GFs and other biological active proteins of PRP can promote tissue healing through the regulation of fibrosis and angiogenesis. Moreover, PRP is considered to be safe due to its autologous nature and long-term usage without any reported major complications. Therefore, PRP therapy could be an option in treating overused tendon damage such as chronic tendinopathy. Here, we present a systematic review highlighting the clinical effectiveness of PRP injection therapy in patellar tendinopathy, which is a major cause of athletes to retire from their respective careers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom